Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 9 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Gritstone Bio Inc. has 13 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 13 distinct examiners and 8 distinct art units. The fact that there are 13 actions and 13 examiners indicates that every pending application is currently being reviewed by a different individual. This one-to-one ratio between 13 pending office actions and 13 distinct examiners suggests a highly decentralized prosecution experience.
CHESTNUT, BARRY A is the busiest examiner, with 1 pending office action. The involvement of 8 distinct art units shows that the company's biotechnology portfolio is spread across several specialized groups. This distribution requires a broad prosecution approach to account for the different standards and examiner behaviors across 13 distinct individuals. Managing 13 pending office actions across 8 distinct art units means the company must be prepared for varied administrative requirements and examination timelines.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (36%) |
| §103 only | 1 (7%) |
| §102 only | 1 (7%) |
| §112 only | 2 (14%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 3 (21%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.5% | +6.4% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| GRIZER, CASSANDRA SENN | 1 | 75.0% | +18.8% |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
| MACFARLANE, STACEY NEE | 1 | 53.5% | +39.6% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16975823 | Neoantigen Identification with Pan-Allele Models | BAILEY, STEVEN WILLIAM | 45d overdue |
| 18658604 | SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF | CHESTNUT, BARRY A | — |
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | GODDARD, LAURA B | — |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | GRIZER, CASSANDRA SENN | — |
| 17817312 | HIV ANTIGENS AND MHC COMPLEXES | LIPPOLIS, ALEXANDRA ROSE | — |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | LEE, YIE CHIA | — |
| 17581788 | NEOANTIGEN IDENTIFICATION USING HOTSPOTS | WOITACH, JOSEPH T | — |
| 17436367 | IDENTIFICATION OF NEOANTIGENS WITH MHC CLASS II MODEL | NGUYEN, PETER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | GODDARD, LAURA B | — |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | GRIZER, CASSANDRA SENN | — |
| 18255539 | COMPOSITIONS AND METHODS OF USE THEREOF | JADHAO, SAMADHAN JAISING | — |
| 18018400 | ENGINEERED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND MANUFACTURE | DAHLE, CHUN WU | — |
| 17426627 | MULTISPECIFIC BINDING PROTEINS | MACFARLANE, STACEY NEE | — |
| 17817312 | HIV ANTIGENS AND MHC COMPLEXES | LIPPOLIS, ALEXANDRA ROSE | — |
| 17838114 | DURABLE VACCINATION | CHEN, STACY BROWN | — |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | LEE, YIE CHIA | — |
| Art Unit | Apps |
|---|---|
| 1672 | 3 |
| 1642 | 2 |
| 1687 | 2 |
| 1641 | 1 |
| 1675 | 1 |
| 1637 | 1 |
| 1638 | 1 |
| 1685 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18658604 | SELF-AMPLIFYING RNA COMPOSITIONS AND METHODS OF USE THEREOF | CHESTNUT, BARRY A | — | §103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18504497 | REDUCING JUNCTION EPITOPE PRESENTATION FOR NEOANTIGENS | GODDARD, LAURA B | 1642 | §101§103§112DP | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18272087 | HOMOLOGOUS ADENOVIRAL VACCINATION | GRIZER, CASSANDRA SENN | 1672 | §103§112 | Non-Final OA | — | Pending | Jul 12, 2023 |
| 18255539 | COMPOSITIONS AND METHODS OF USE THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18018400 | ENGINEERED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND MANUFACTURE | DAHLE, CHUN WU | 1641 | §112 | Non-Final OA | — | Pending | Jan 27, 2023 |
| 17426627 | MULTISPECIFIC BINDING PROTEINS | MACFARLANE, STACEY NEE | 1675 | §112 | Non-Final OA | — | Pending | Sep 16, 2022 |
| 17817312 | HIV ANTIGENS AND MHC COMPLEXES | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Non-Final OA | — | Pending | Aug 03, 2022 |
| 17838114 | DURABLE VACCINATION | CHEN, STACY BROWN | 1672 | §103§112DP | Final Rejection | — | Pending | Jun 10, 2022 |
| 17744354 | ANTIGEN-BINDING PROTEINS TARGETING SHARED NEOANTIGENS | LEE, YIE CHIA | 1642 | §101§102§103§112 | Non-Final OA | — | Pending | May 13, 2022 |
| 17736738 | SHARED NEOANTIGEN VACCINES | VIVLEMORE, TRACY ANN | 1638 | §102Other | Final Rejection | 141d overdue | Pending | May 04, 2022 |
| 17581788 | NEOANTIGEN IDENTIFICATION USING HOTSPOTS | WOITACH, JOSEPH T | 1687 | §101§112Other | Non-Final OA | — | Pending | Jan 21, 2022 |
| 17436367 | IDENTIFICATION OF NEOANTIGENS WITH MHC CLASS II MODEL | NGUYEN, PETER | 1685 | §101§103DP | Final Rejection | — | Pending | Sep 03, 2021 |
| 17433817 | SELECTION OF T CELL RECEPTORS | FAUST, AMBER KATHLEEN | 1643 | §103 | Final Rejection | — | Pending | Aug 25, 2021 |
| 16975823 | Neoantigen Identification with Pan-Allele Models | BAILEY, STEVEN WILLIAM | 1687 | §101§103§112DP | Final Rejection | 45d overdue | Pending | Aug 26, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial